These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 21544960)
1. Advances in the design of 5-HT6 receptor ligands with therapeutic potential. Witty D; Ahmed M; Chuang TT Prog Med Chem; 2009; 48():163-224. PubMed ID: 21544960 [No Abstract] [Full Text] [Related]
2. The therapeutic potential of 5-HT6 receptor antagonists. Reavill C; Rogers DC Curr Opin Investig Drugs; 2001 Jan; 2(1):104-9. PubMed ID: 11527001 [No Abstract] [Full Text] [Related]
3. 5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia. Johnson CN; Ahmed M; Miller ND Curr Opin Drug Discov Devel; 2008 Sep; 11(5):642-54. PubMed ID: 18729016 [TBL] [Abstract][Full Text] [Related]
4. 5-HT6 receptor ligands and their antipsychotic potential. Arnt J; Olsen CK Int Rev Neurobiol; 2011; 96():141-61. PubMed ID: 21329787 [No Abstract] [Full Text] [Related]
5. The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update. Khoury R; Grysman N; Gold J; Patel K; Grossberg GT Expert Opin Investig Drugs; 2018 Jun; 27(6):523-533. PubMed ID: 29848076 [TBL] [Abstract][Full Text] [Related]
6. Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease. Wicke K; Haupt A; Bespalov A Expert Opin Investig Drugs; 2015; 24(12):1515-28. PubMed ID: 26548316 [TBL] [Abstract][Full Text] [Related]
7. In the search for selective ligands of 5-HT5, 5-HT6 and 5-HT7 serotonin receptors. Wesołowska A Pol J Pharmacol; 2002; 54(4):327-41. PubMed ID: 12523486 [TBL] [Abstract][Full Text] [Related]
9. [Physiopathological and therapeutic perspectives on the new serotonin receptors: the type 4 receptor]. Lefebvre H Rev Med Interne; 2000 Aug; 21(8):661-3. PubMed ID: 10989490 [No Abstract] [Full Text] [Related]
10. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease. Geldenhuys WJ; Van der Schyf CJ Expert Rev Neurother; 2009 Jul; 9(7):1073-85. PubMed ID: 19589055 [TBL] [Abstract][Full Text] [Related]
12. The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia. Nikiforuk A Rev Neurosci; 2014; 25(3):367-82. PubMed ID: 24501158 [TBL] [Abstract][Full Text] [Related]
13. The 5-HT1A receptor and its ligands: structure and function. Olivier B; Soudijn W; van Wijngaarden I Prog Drug Res; 1999; 52():103-65. PubMed ID: 10396127 [TBL] [Abstract][Full Text] [Related]
14. Serotonin receptors of type 6 (5-HT6): what can we expect from them? Marazziti D; Baroni S; Catena Dell'Osso M; Bordi F; Borsini F Curr Med Chem; 2011; 18(18):2783-90. PubMed ID: 21649582 [TBL] [Abstract][Full Text] [Related]
15. Recent advances in 5-HT1B/1D receptor antagonists and agonists and their potential therapeutic applications. Slassi A Curr Top Med Chem; 2002 Jun; 2(6):559-74. PubMed ID: 12052194 [TBL] [Abstract][Full Text] [Related]
16. 5-HT6 receptor agonist and antagonist modulates ICV-STZ-induced memory impairment in rats. Bokare AM; Bhonde M; Goel R; Nayak Y Psychopharmacology (Berl); 2018 May; 235(5):1557-1570. PubMed ID: 29502275 [TBL] [Abstract][Full Text] [Related]